LGM Pharma accelerates & optimizes the new product pathway from early development through commercialization.
01 1LGM Pharma
02 1Shanghai Minbiotech
03 1Biotechnica DWC
04 1Celltrion
05 1KinBio
01 1Algeria
02 1China
03 1Israel
04 1South Korea
05 1U.S.A
01 5Blank
01 5Blank
01 1225MF10184
02 4Blank
01 5Blank
LGM Pharma accelerates & optimizes the new product pathway from early development through commercialization.
Shanghai Minbiotech is the leading producer of biopharmaceuticals and a variety of high-end generic & innovative drugs.
Registration Number : 225MF10184
Registrant's Address : 19, Academy-ro 51beon-gil, Yeonsu-gu, Incheon, 22014, Korea
Initial Date of Registration : 2013-09-25
Latest Date of Registration : --
NDC Package Code : 32228-001
Start Marketing Date : 2016-11-08
End Marketing Date : 2025-12-31
Dosage Form (Strength) : INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION (100mg/10mL)
Marketing Category : DRUG FOR FURTHER PROCESSING
We have 5 companies offering Infliximab
Get in contact with the supplier of your choice:
LOOKING FOR A SUPPLIER?
